Li Lijun Li

US Patent:

20100113908, May 6, 2010

Filed:

Oct 30, 2009

Appl. No.:

12/609304

Inventors:

Steve Vargas - Sun Valley CA, US
Robin Boyce - Pleasanton CA, US
Li Li - Milpitas CA, US
Hui Wang - San Ramon CA, US
Scott Amundson - Oakland CA, US
James Ochs - Seattle WA, US
Tonia Madere - Stockton CA, US

Assignee:

Nellcor Puritan Bennett LLC - Boulder CO

International Classification:

A61B 5/145

US Classification:

600364

Abstract:

Present embodiments are directed to a system and method capable of detecting and graphically indicating physiologic patterns in patient data. For example, present embodiments may include a monitoring system that includes a monitor capable of receiving input relating to patient physiological parameters and storing historical data related to the parameters. Additionally, the monitoring system may include a screen capable of displaying the historical data corresponding to the patient physiological parameters. Further, the monitoring system may include a pattern detection feature capable of analyzing the historical data to detect a physiologic pattern in a segment of the historical data and capable of initiating a graphical indication of the segment on the screen when the physiologic pattern is present in the segment.

US Patent:

20130195795, Aug 1, 2013

Filed:

Nov 8, 2012

Appl. No.:

13/672417

Inventors:

Amgen Inc. - Thousand Oaks CA, US
Li LI - Sammamish WA, US

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

C07K 14/55

US Classification:

424 852, 530351, 435375

Abstract:

Described herein are immunosuppressive molecules including immunosuppressive variants of IL-2, and use of such molecules to treat inflammatory and autoimmune disorders.

US Patent:

20140343252, Nov 20, 2014

Filed:

Mar 13, 2014

Appl. No.:

14/209914

Inventors:

- Thousand Oaks CA, US
Gunasekaran KANNAN - Newbury Park CA, US
Li LI - Sammamish WA, US
Joshua T. PEARSON - Seattle WA, US
Margaret KAROW - Santa Rosa Valley CA, US

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

C07K 14/55
C07K 16/00

US Classification:

530351, 5303873, 435 696

Abstract:

Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.

US Patent:

20140286898, Sep 25, 2014

Filed:

Mar 13, 2014

Appl. No.:

14/209699

Inventors:

- Thousand Oaks CA, US
Gunasekaran KANNAN - Newbury Park CA, US
Li LI - Sammamish WA, US
Joshua T. PEARSON - Seattle WA, US
Margaret KAROW - Santa Rosa Valley CA, US

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

C07K 14/55
C07K 16/18

US Classification:

424 852, 530351, 536 235, 536 234, 4353201, 43525233, 435325, 435358, 435 6952, 435 697, 435375

Abstract:

Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.